

China Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032

Market Report | 2023-06-01 | 88 pages | Allied Market Research

AVAILABLE LICENSES:

- Cloud Access License \$1957.50
- Business User License \$2929.50
- Enterprise License \$4549.50

Report description:

The China point-of-care glucose testing is primarily influenced by several significant factors. One of the major factors that is driving the market is presence of an aging population in China, coupled with an increase in awareness surrounding the management of diabetes. This has led to a greater emphasis on regular glucose testing, resulting in a significant increase in the number of patients and healthcare professionals opting for point-of-care testing solutions. These innovative devices offer instantaneous results, allowing for swift adjustments in treatment plans and lifestyle modifications. Moreover, surge in the prevalence of diabetes in China is contributing to the market's persistent growth. As the number of individuals diagnosed with diabetes continues to surge, the demand for efficient point-of-care glucose testing devices is increasing. This surge in demand is leading to the rapid expansion of the market. Furthermore, rise in the focus on early disease detection and management is driving the adoption of these devices in both clinical and home care settings.

On the other hand, the market's intricate dynamics are not devoid of obstacles. Regulatory obstacles and persistent presence in the healthcare sector represent one of the main constraints in the market growth. Acquiring the requisite approvals and certifications for point-of-care glucose testing products is expected to be a laborious and resource-intensive undertaking. These regulatory complexities frequently act as barriers for new participants, thereby increasing competition among established market players. However, the future of the market presents the potential for innovation, expansion, and evolution. The continuously broadening scope of applications for point-of-care glucose testing devices persistently reveals new opportunities. Apart from the conventional uses for type-1 and type-2 diabetes, these devices prove useful in various clinical situations. In addition, emergence of applications in monitoring gestational diabetes and perioperative care broadens the market's perspectives, providing avenues for growth that were previously concealed.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The China point-of-care glucose testing market is segmented into product type, application, and end user. Further, on the basis of product type, the market is segregated into lancing devices & strips and blood-glucose meter. Depending on application, it is bifurcated into type-1 diabetes and type-2 diabetes. By end user, the market is classified into hospitals & clinics, home care settings, and others. These market players are making significant investments in R&D to create devices that provide improved accuracy in readings, require smaller blood samples, and enable effortless transmission of data to mobile applications and healthcare providers. In addition, manufacturers are presently prioritizing cost-effective product development while ensuring the accessibility of their devices. A common approach utilized to cater to various customer segments involves offering a variety of pricing tiers and subscription models for connected services.

The Porter's five forces analysis analyzes the competitive scenario of the China point-of-care glucose testing market and role of each stakeholder. These forces include the bargaining power of suppliers, bargaining power of buyers, threat of new entrants, threat of substitutes, and competitive rivalry. The threat of new entrants poses a complex challenge within the market. The existence of regulatory obstacles and the requirement for significant financial investments establish formidable obstacles for aspiring entrants. The complexity is compounded by significant bargaining power of suppliers. Suppliers possess considerable influence due to the market's reliance on cutting-edge technology and superior components, rendering them indispensable. Consequently, this intricate scenario gives rise to a multifaceted interplay of negotiation and collaboration.

The bargaining power of buyers is a persistent reminder of the price sensitivity of the Chinese market. The market is characterized by economic diversity, and buyers, comprising healthcare institutions and individual consumers, wield significant influence. The threat of substitute poses a significant risk, as it introduces an element of unpredictability. With the continuous advancement of technology, there is a possibility of new glucose testing methods emerging, which potentially challenge the effectiveness of conventional devices. Therefore, it is imperative for market participants to maintain a state of constant vigilance in their pursuit of innovation to maintain a competitive edge.

The competitive rivalry is the driving force of the market. As established players compete for dominance and new entrants endeavor to establish their presence, competition is intense and constantly evolving. The market's complex dynamics unfold within this competitive landscape. A thorough comprehension of the market would be inadequate without consideration of its internal strengths and weaknesses, and external opportunities and threats it confronts. This consideration, similar to a SWOT analysis, reveals some aspects of the China point-of-care glucose testing market.

The market's strengths are rooted in its unwavering commitment to innovation and adaptability. Its capacity to embrace emerging technologies, address evolving healthcare demands, and expand its range of applications positions it as a dynamic and influential force. Furthermore, its strategic emphasis on patient-centric solutions further enhances its robustness. Nevertheless, this dynamic market harbors inherent weaknesses. The intricate regulatory framework, characterized by protracted approval procedures, has the potential to impede innovation and hinder market entry. In addition, economic fluctuations in China, which serve as a backdrop to the market's narrative, introduce an element of unpredictability.

Opportunities manifest themselves within this market, including increase in utilization of point-of-care glucose testing devices, coupled with rise in the incidence of diabetes, present avenues for market expansion. In addition, increase in emphasis on home care environments and the empowerment of patients give rise to novel prospects for growth. However, the market is not devoid of its threats. Price sensitivity and resource constraints pose a substantial challenge. Moreover, rise in threat of emerging technologies capable of disrupting the current market further exacerbates the situation. In conclusion, the China point-of-care glucose testing market is expected to be characterized as a multifaceted landscape of innovation and intricacy. It is a market propelled by unwavering commitment to accuracy, intricacies of regulatory frameworks, and vast potential for groundbreaking advancements.

Key players operating in the China point-of-care glucose testing market include Roche, Abbott, Siemens Healthcare, Johnson & Johnson, Medtronic, A. Menarini Diagnostics, Biosense Medical, Sannuo Medical Technologies, Optimum Diagnostics, and Sysmex Biomedical.

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in China point-of-care glucose testing market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Assess and rank the top factors that are expected to affect the growth of China point-of-care glucose testing market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the China point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

- Product Benchmarking / Product specification and applications
- Upcoming/New Entrant by Regions
- New Product Development/ Product Matrix of Key Players
- Patient/epidemiology data at country, region, global level
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis

Key Market Segments

By Product Type

- Lancing Devices and Strips
- Blood-Glucose Meter

? Type

? Lifescan OneTouch Ultra and Lifescan OneTouch Verio

? Accu-Chek Aviva Plus and Accuchek

? Freestyle Lite and Freestyle Precision Neo

? Contour Next

? Others

By Application

- Type-1 Diabetes
- Type-2 Diabetes

By End User

- Hospitals and Clinics
- Home Care Settings
- Others
- Key Market Players

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

? Roche
? Abbott
? Siemens Healthcare
? Johnson & Johnson
? Medtronic
? A. Menarini Diagnostics
? Biosense Medical
? Sannuo Medical Technologies
? Optimum Diagnostics
? Sysmex Biomedical

Table of Contents:

CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology
 - 1.4.1. Primary Research
 - 1.4.2. Secondary Research
 - 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market Definition and Scope
- 3.2. Key Findings
 - 3.2.1. Top Impacting Factors
 - 3.2.2. Top Investment Pockets
- 3.3. Porter's Five Forces Analysis
- 3.4. Market Dynamics
 - 3.4.1. Drivers
 - 3.4.2. Restraints
 - 3.4.3. Opportunities
- 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE

- 4.1. Overview
 - 4.1.1. Market Size and Forecast, By Product Type
- 4.2. Lancing Devices and Strips
- 4.3. Blood-Glucose Meter

CHAPTER 5: CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION

- 5.1. Overview
 - 5.1.1. Market Size and Forecast, By Application
- 5.2. Type-1 Diabetes
- 5.3. Type-2 Diabetes

CHAPTER 6: CHINA POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER

- 6.1. Overview
 - 6.1.1. Market Size and Forecast, By End User
- 6.2. Hospitals and Clinics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.3. Home Care Settings

6.4. Others

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. Roche

8.1.1. Company overview

8.1.2. Key Executives

8.1.3. Company snapshot

8.1.4. Operating business segments

8.1.5. Product portfolio

8.1.6. Business performance

8.1.7. Key strategic moves and developments

8.2. Abbott

8.2.1. Company overview

8.2.2. Key Executives

8.2.3. Company snapshot

8.2.4. Operating business segments

8.2.5. Product portfolio

8.2.6. Business performance

8.2.7. Key strategic moves and developments

8.3. Siemens Healthcare

8.3.1. Company overview

8.3.2. Key Executives

8.3.3. Company snapshot

8.3.4. Operating business segments

8.3.5. Product portfolio

8.3.6. Business performance

8.3.7. Key strategic moves and developments

8.4. Johnson & Johnson

8.4.1. Company overview

8.4.2. Key Executives

8.4.3. Company snapshot

8.4.4. Operating business segments

8.4.5. Product portfolio

8.4.6. Business performance

8.4.7. Key strategic moves and developments

8.5. Medtronic

8.5.1. Company overview

8.5.2. Key Executives

8.5.3. Company snapshot

8.5.4. Operating business segments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.5.5. Product portfolio
- 8.5.6. Business performance
- 8.5.7. Key strategic moves and developments
- 8.6. A. Menarini Diagnostics
 - 8.6.1. Company overview
 - 8.6.2. Key Executives
 - 8.6.3. Company snapshot
 - 8.6.4. Operating business segments
 - 8.6.5. Product portfolio
 - 8.6.6. Business performance
 - 8.6.7. Key strategic moves and developments
- 8.7. Biosense Medical
 - 8.7.1. Company overview
 - 8.7.2. Key Executives
 - 8.7.3. Company snapshot
 - 8.7.4. Operating business segments
 - 8.7.5. Product portfolio
 - 8.7.6. Business performance
 - 8.7.7. Key strategic moves and developments
- 8.8. Sannuo Medical Technologies
 - 8.8.1. Company overview
 - 8.8.2. Key Executives
 - 8.8.3. Company snapshot
 - 8.8.4. Operating business segments
 - 8.8.5. Product portfolio
 - 8.8.6. Business performance
 - 8.8.7. Key strategic moves and developments
- 8.9. Optimum Diagnostics
 - 8.9.1. Company overview
 - 8.9.2. Key Executives
 - 8.9.3. Company snapshot
 - 8.9.4. Operating business segments
 - 8.9.5. Product portfolio
 - 8.9.6. Business performance
 - 8.9.7. Key strategic moves and developments
- 8.10. Sysmex Biomedical
 - 8.10.1. Company overview
 - 8.10.2. Key Executives
 - 8.10.3. Company snapshot
 - 8.10.4. Operating business segments
 - 8.10.5. Product portfolio
 - 8.10.6. Business performance
 - 8.10.7. Key strategic moves and developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

China Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032

Market Report | 2023-06-01 | 88 pages | Allied Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Cloud Access License	\$1957.50
	Business User License	\$2929.50
	Enterprise License	\$4549.50
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-08

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com